Complex therapy of recurrent urinary infections

   Recurrent urinary tract infections (RUTI) occur in 10-15 % of women of reproductive age and in 20 % of menopausal women and have an extremely negative impact on quality of life. Urinary tract infections (UTIs) account for about 40 % of all hospital-acquired infections and 50% of bacterial infections resulting in long-term hospitalisation. In Russia, 26-36 million cases of acute cystitis are reported each year. Because of its high prevalence, UTI is an economic problem. Clinically, UTI is more often manifested as acute urethritis or cystitis. Antibiotic therapy is a fundamental treatment for RUTI, but has a number of negative consequences. Antimicrobial resistance is an enormous challenge and a serious threat to global health, prompting the search for alternative strategies. Natural antimicrobial peptides have attracted the attention of researchers and clinicians for their broad therapeutic potential against bacteria, viruses and resistant intracellular bacterial communities (biofilms). This review details the etiology, classification, diagnosis and therapy of RUTI. Global data revealing the mechanisms of action of antimicrobial peptides is presented. Commercially available peptide-based antimicrobials and their efficacy based on clinical trials are discussed. The development of new strategies to combat bacterial infections, in particular the use of drugs based on antimicrobial peptides and their derivatives, has been shown to be of great practical importance in terms of combating multidrug-resistant pathogens and increasing the effectiveness of treatment of recurrent infections.

1. Foxman B. The epidemiology of urinary tract infection. Nat Rev Urol. 2010; 7 (12): 653–660. https://doi.org/10.1038/nrurol.2010.190.

2. Asadi Karam M. R., Habibi M., Bouzari S. Urinary tract infection: Pathogenicity, antibiotic resistance and development of effective vaccines against Uropathogenic Escherichia coli. Mol Immunol. 2019; (108): 56–67. https://doi.org/10.1016/j.molimm.2019.02.007.

3. Лоран О. Б. Воспалительные заболевания органов мочевой системы. Актуальные вопросы. / О. Б. Лоран, Л. А. Синякова. – 4-е изд., переработанное и дополненное. – М.: МИА, 2014. – 84 с. Режим доступа: https://search.rsl.ru/ru/record/01007858442. – Loran O. B., Sinyakova L. A. Inflammatory diseases of the urinary system. Topical issues. 4th ed. Moscow: MIA; 2014. 84 p. (In Russ.) Available at: https://search.rsl.ru/ru/record/01007858442.

4. Mann R., Mediati D. G., Duggin I. G., Harry E. J., Bottomley A. L. Metabolic adaptations of uropathogenic E. coli in the urinary tract. Front Cell Infect Microbiol. 2017; (7): 241. https://doi.org/10.3389/fcimb.2017.00241.

5. Haylen B. T., de Ridder D., Freeman R. M., Swift S. E., Berghmans B., Lee J. et al. An International Urogynecological Association (IUGA) / International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn. 2010; 29( 1): 4–20. https://doi.org/10.1002/nau.20798.

6. Hooton T. M. Recurrent urinary tract infection in women. Int J Antimicrob Agents. 2010; 17 (4): 259–268. https://doi.org/10.1016/S0924-8579(00)00350-2.

7. Foxman B. Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden. Infect Dis Clin North Am. 2014; 28 (1): 1–13. https://doi.org/10.1016/j.idc.2013.09.003.

8. Mody L., Juthani-Mehta M. Urinary tract infections in older women. JAMA. 2014; 311 (8): 844–854. https://doi.org/10.1001/jama.2014.303.

9. Laupland K. B., Ross T., Pitout J. D., Church D. L., Gregson D. B. Community-onset urinary tract infections: a population- based assessment. Infection. 2007; 35 (3): 150–153. https://doi.org/10.1007/s15010-007-6180-2.

10. Zacchè M. M., Giarenis I. Review UroPathogenic Escherichia coli (UPEC) Infections: Virulence Factors, Bladder Responses, Antibiotic, and Non-antibiotic Antimicrobial Strategies. Expert Opin Investig Drugs. 2016; 25 (5): 531–540. https://doi.org/10.1517/13543784.2016.1161024.

11. Hof H. Review Metabolic Adaptations of Uropathogenic E. coli in the Urinary Tract. Urologe A. 2017; 56 (2): 172–179. https://doi.org/10.3389/fcimb.2017.00241.

12. Перепанова Т. С. Федеральные клинические рекомендации. Антимикробная терапия и профилактика инфекций почек, мочевыводящих путей и мужских половых органов / Т. С. Перепанова // Терапевтический архив. – 2016. – (4): 100–104. https://doi.org/10.17116/terarkh2016884100-104. – Perepanova T. S. The 2015 Federal Clinical Guidelines for Antimicrobial Therapy and Prevention of Infections of the Kidney, Urinary Tract, and Male Genitals. Terapevticheskii Arkhiv. 2016;(4):100–104. (In Russ.) https://doi.org/10.17116/terarkh2016884100-104.

13. Перепанова Т. С. Цистит у женщин: клинические рекомендации / Т. С. Перепанова, Л. А. Синякова, К. Л. Локшин. – М., 2021. Режим доступа: https://cr.minzdrav.gov.ru/recomend/14_2. – Perepanova T. S., Sinyakova L. A., Lokshin K. L. Cystitis in women: clinical guidelines. Мoscow; 2021. (In Russ.) Available at: https://cr.minzdrav.gov.ru/recomend/14_2.

14. Apodaca G. The Uroepithelium: Not Just a Passive Barrier. Traffic. 2004; 5 (3): 117–128. https://doi.org/10.1046/j.1600-0854.2003.00156.x.

15. Kot B. Antibiotic Resistance Among Uropathogenic Escherichia coli. Pol J Microbiol. 2019; 68 (4): 403–415. URL: https://pubmed.ncbi.nlm.nih.gov/31880885/.

16. Flores-Mireles A. L., Walker J. N., Caparon M., Hultgren S. J. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat Rev Microbiol. 2015; 13 (5): 269–284. https://doi.org/10.1038/nrmicro3432.

17. Wagenlehner F. M., Hoyme U., Kaase M., Funfstuck R., Naber K. G., Schiemann G. Uncomplicated urinary tract infections. Dtsch Arztebl Int. 2011; 108 (24): 415–423. https://doi.org/10.3238/arztebl.2011.0415.

18. Gupta K., Hooton T. M., Naber K. G., Wullt B., Colgan R., Miller L. G. et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011; 52 (5): 103–120. https://doi.org/10.1093/cid/ciq257.

19. Перепанова Т. С. Цистит бактериальный у взрослых: клинические рекомендации 2019 / Т. С. Перепанова, Л. А. Синякова, К. Л. Локшин. – М., 2019. – 32 с. Режим доступа: https://bz.medvestnik.ru/nosology/Cistit-bakterialnyi-u-vzroslyh.html. – Perepanova T. S., Sinyakova L. A., Lokshin K. L. Bacterial cystitis in adults: clinical guidelines. 2019. Мoscow; 2019. 32 p. (In Russ.) https://bz.medvestnik.ru/nosology/Cistit-bakterialnyi-u-vzroslyh.html.

20. Kranz J., Schmidt S., Schneidewind L. Current Evidence on Nonantibiotic Prevention of Recurrent Urinary Tract Infection. Eur Urol Focus. 2019; 5 (1): 17–19. https://doi.org/10.1016/j.euf.2018.09.006.

21. Fisher H., Oluboyede Y., Chadwick T., Abdel-Fattah M., Brennand C., Fader M. et al. Continuous low-dose antibiotic prophylaxis for adults with repeated urinary tract infections (AnTIC): a randomised, open-label trial. Lancet Infect Dis. 2018; 18 (9): 957–968. https://doi.org/10.1016/S1473-3099(18)30279-2.

22. Egrot C., Dinh A., Amarenco G., Bernard L., Birgand G., Bruyere F. et al. Antibiotic prophylaxis in urodynamics: Clinical practice guidelines using a formal consensus method. Prog Urol. 2018; 28 (17): 943–952. https://doi.org/10.1016/j.purol.2018.10.001.

23. Tenney J., Hudson N., Alnifaidy H., Li J. T. C., Fung K. H. Risk factors for aquiring multidrug-resistant organisms in urinary tract infections: A systematic literature review. Saudi Pharm J. 2018; 26 (5): 678–684. https://doi.org/10.1016/j.jsps.2018.02.023.

24. Cek M., Tandoğdu Z., Wagenlehner F., Tenke P., Naber K., Bjerklund-Johansen T. E. Healthcare-associated urinary tract infections in hospitalized urological patients – a global perspective: results from the GPIU studies 2003–2010. World J Urol. 2014; 32 (6): 1587–1594. https://doi.org/10.1007/s00345-013-1218-9.

25. Thomas C. M., Nielsen K. M. Mechanisms of, and barriers to, horizontal gene transfer between bacteria. Nat Rev Microbiol. 2005; 3: 711–721. https://doi.org/10.1038/nrmicro1234.

26. Madsen J. S., Burmolle M., Hansen L. H., Sorensen S. J. The interconnection between biofilm formation and horizontal gene transfer. FEMS Immunol Med Microbiol. 2012; 65 (2): 183–195. https://doi.org/10.1111/j.1574-695X.2012.00960.x.

27. Graziottin A., Zanello P. P., D’Errico G. Recurrent cystitis and vaginitis: role of biofilms and persister cells. From pathophysiology to new therapeutic strategies. Minerva Ginecol. 2014; 66 (5): 497–512. Available at: https://pubmed.ncbi.nlm.nih.gov/25245998/.

28. Diamond G., Beckloff N., Weinberg A., Kisich K. O. The roles of antimicrobial peptides in innate host defense. Curr Pharm Des. 2009; 15 (21): 2377–2392. https://doi.org/10.2174/138161209788682325.

29. Zhang L. J., Gallo R. L. Antimicrobial peptides. Curr Biol. 2016; 26 (1): R14–R19. https://doi.org/10.1016/j.cub.2015.11.017.

30. Lai Y., Gallo R. L. AMPed up immunity: How antimicrobial peptides have multiple roles in immune defense. Trends Immunol. 2009; 30 (3): 131–141. https://doi.org/10.1016/j.it.2008.12.003.

31. Lemaitre B., Nicolas E., Michaut L., Reichhart J. M., Hoffmann J. A. The dorsoventral regulatory gene cassette spatzle / Toll / cactus controls the potent antifungal response in Drosophila adults. Cell. 1996; 86 (6): 973–983. https://doi.org/10.1016/S0092-8674(00)80172-5.

32. Lei J., Sun L., Huang S., Zhu C., Li P., He J. et al The antimicrobial peptides and their potential clinical applications. Am J Transl Res. 2019; 11 (7): 3919–3931. Available at: https://pubmed.ncbi.nlm.nih.gov/31396309/.

33. Browne K., Chakraborty S., Chen R., Willcox M. D., StClair Black D., Walsh W. R., Kumar N. A New Era of Antibiotics: The Clinical Potential of Antimicrobial Peptides. Int J Mol Sci. 2020; 21 (19): 7047. https://doi.org/10.3390/ijms21197047.

34. Jenssen H., Hamill P., Hancock R. E. Peptide antimicrobial agents. Clin Microbiol Rev. 2006; 19 (3): 491–511. https://doi.org/10.1128/CMR.00056-05.

35. Chung P. Y., Khanum R. Antimicrobial peptides as potential anti-biofilm agents against multidrug-resistant bacteria. J Microbiol Immunol Infect. 2017; 50 (4): 405–410. https://doi.org/10.1016/j.jmii.2016.12.005.

36. Bucki R., Leszczynska K., Namiot A., Sokolowski W. Cathelicidin LL-37: A multitask antimicrobial peptide. Arch Immunol Ther Exp. 2010; 58 (1): 15–25. https://doi.org/10.1007/s00005-009-0057-2.

37. Ma Z., Kochergin N., Olisova O., Snarskaya E. Ma. Z Topical antimicrobial peptides in combined treatment of acne patients. J Cosmet Dermatol. 2022; 21 (4): 1533–1538. https://doi.org/10.1111/jocd.14300.

38. Obuobi S., Tay H. K., Tram N. D. T., Selvarajan V., Khara J. S., Wang Y., Ee P. L. R. Obuobi S Facile and efficient encapsulation of antimicrobial peptides via crosslinked DNA nanostructures and their application in wound therapy. J Control Release. 2019; 10 (313): 120–130. https://doi.org/10.1016/j.jconrel.2019.10.013.

39. Ahmad A., Ahmad E., Rabbani G., Haque S., Arshad M., Khan R. H. Ahmad A., Identification and design of antimicrobial peptides for therapeutic applications. Curr Protein Pept Sci. 2012; 13 (3): 211–223. https://doi.org/10.2174/138920312800785076.

40. Kuhlmann N., Nehls C., Heinbockel L., Correa W., Moll R., Gutsmann T. et al. Encapsulation and release of As pidasept peptides in polysaccharide formulation for oral application. Eur J Pharm Sci. 2021; 1 (158): 105687. https://doi.org/10.1016/j.ejps.2020.105687.

41. Доброхотова Ю. Э. Колонизационная резистентность и напряженность факторов врожденного иммунитета слизистых влагалища у пациенток с хроническим эндометритом / Ю. Э. Доброхотова [и др.] // Вопросы гинекологии, акушерства и перинатологии. – 2019. –18 (2): 48–56. https://doi.org/10.20953/1726-1678-2019-2-48-56. – Dobrokhotova Yu. E., Gankovskaya L. V, Borovkova E. I., Danelyan S. Zh., Svitich O. A., Zalesskaya S. A. et al. Resistance and levels of innate immune factors of the vaginal mucosa in patients with chronic endometritis. Gynecology, Obstetrics and Perinatology. 2019; 18 (2): 48–56. (In Russ.) https://doi.org/10.20953/1726-1678-2019-2-48-56.

42. Кореева Н. В. Локальная цитокинотерапия в гинекологической практике (обзор литературы) / Н. В. Кореева, Ю. Э. Доброхотова // Проблемы репродукции. – 2013. – (4): 21–26. Режим доступа: https://www.mediasphera.ru/issues/problemy-reproduktsii/2013/4/031025-7217201345. – Koreeva N. V., Dobrokhotova Iu. E. Topical cytokinotherapy in gynecological practice (a review). Russian Journal of Human Reproduction. 2013; (4): 21–26. (In Russ.) Available at: https://www.mediasphera.ru/issues/problemy-reproduktsii/2013/4/031025-7217201345.

43. Хурасева А. Б. Оптимизация лечения цервицитов в раннем репродуктивном возрасте с помощью локальной цитокинотерапии / А. Б. Хурасева [и др.] // Российский вестник акушера­-гинеколога. – 2016. – (3): 48–51. https://doi.org/10.17116/rosakush201616348-51. – Khuraseva A. B., Gaidarova A. Kh., Manzhosova M. I., Rogovskaia S. I. Optimization of local cytokine therapy for cervititis at an early reproductive age. Russian Bulletin of Obstetrician­ Gynecologist. 2016; (3): 48–51. (In Russ.) https://doi.org/10.17116/rosakush201616348-51.

44. Абакарова П. Р. Локальная цитокинотерапия в комплексном лечении ВПЧ-ассоциированных заболеваний шейки матки / П. Р. Абакарова [и др.] // Гинекология. – 2019. – 21 (1): 28–32. https://doi.org/10.26442/20795696.2019.1.190284. – Abakarova P. R., Prilepskaya V. N., Mezhevitinova E. A., Donnikov A. E. Local cytokine therapy in a comprehensive treatment of HPV-associated cervical disease. Gynecology. 2019; 21 (1): 28–32. (In Russ.) https://doi.org/10.26442/20795696.2019.1.190284.

45. Тапильская Н. И. Эффективность локальной цитокинотерапии хронического эндометрита у пациенток с бесплодием / Н. И. Тапильская [и др.] // Акушерство и гинекология. – 2022. – (2): 91–99. https://doi.org/10.18565/aig.2022.2.91-100. – Tapilskaya N. I., Tolibova G. Kh., Savicheva A. M., Kopylova A. A., Glushakov R. I., Budilovskaya O. V. et al. The effectiveness of local cytokine therapy for chronic endometritis in patients with infertility. Akusherstvo i Ginekologiya (Russian Federation). 2022; (2): 91–99. (In Russ.) https://doi.org/10.18565/aig.2022.2.91-100.

46. Аполихина И. А. Эффективность применения локальной цитокинотерапии в комплексном лечении пациенток с хроническим циститом / И. А. Аполихина, А. С. Саидова, Т. А. Тетерина // Акушерство и гинекология. – 2019. – (12): 167–173. https://doi.org/10.18565/aig.2019.12.167-172. – Apolikhina I. A., Saidova A. S., Teterina T. A. Efficiency of local cytokine therapy used in the combination treatment of female patients with chronic cystitis. Akusherstvo i Ginekologiya (Russian Federation). 2019; (12): 167–173. (In Russ.) https://doi.org/10.18565/aig.2019.12.167-172.